Hosking Partners LLP Sells 7,118 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Hosking Partners LLP cut its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 11.5% in the fourth quarter, Holdings Channel reports. The fund owned 54,992 shares of the medical research company’s stock after selling 7,118 shares during the period. Hosking Partners LLP’s holdings in Bio-Rad Laboratories were worth $18,065,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Strategic Financial Concepts LLC acquired a new stake in shares of Bio-Rad Laboratories during the 4th quarter worth about $3,561,000. Lecap Asset Management Ltd. acquired a new stake in shares of Bio-Rad Laboratories during the fourth quarter worth approximately $510,000. Principal Financial Group Inc. raised its stake in shares of Bio-Rad Laboratories by 95.6% in the third quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock valued at $14,836,000 after acquiring an additional 21,669 shares during the last quarter. Mawer Investment Management Ltd. boosted its holdings in shares of Bio-Rad Laboratories by 63.0% in the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock worth $72,900,000 after acquiring an additional 84,237 shares in the last quarter. Finally, Verition Fund Management LLC grew its position in Bio-Rad Laboratories by 193.3% during the 3rd quarter. Verition Fund Management LLC now owns 3,470 shares of the medical research company’s stock worth $1,161,000 after acquiring an additional 2,287 shares during the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Price Performance

Shares of BIO stock opened at $265.31 on Friday. The firm’s 50 day moving average price is $328.27 and its two-hundred day moving average price is $332.89. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. Bio-Rad Laboratories, Inc. has a 52-week low of $262.12 and a 52-week high of $387.99. The stock has a market cap of $7.43 billion, a PE ratio of -4.08 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on BIO shares. StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Citigroup upped their target price on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Wells Fargo & Company lowered their price target on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Bio-Rad Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $395.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.